Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE PPARα agonists (fibrates) and PPARγ agonists (thiazolidinediones) are used for the treatment of hypertriglyceridemia and type 2 diabetes, respectively. 31825687 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, reduces lower limb amputations in patients with type 2 diabetes.The mechanism is, however, unknown. 30765336 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE For example, certain TZDs have been reported to ameliorate type II diabetes by binding and activating PPARs (peroxisome proliferator-activated receptors). 31163649 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE We will aim to evaluate the effects of resveratrol supplementation on mRNA expression of PPARα, p53, p21 and p16 in patients with T2D. 31278094 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial. 31831868 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE The Effect of Aleglitazar on Cardiovascular Outcomes after Acute Coronary Syndrome in Patients with Type 2 Diabetes Mellitus trial compared the peroxisome proliferator-activated receptor-α/γ agonist aleglitazar with placebo in patients with type 2 diabetes and recent ACS. 29659887 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM-α), pemafibrate, will be used to target residual cardiovascular risk remaining after treatment to reduce low-density lipoprotein cholesterol (LDL-C) in individuals with the dyslipidemia of type 2 diabetes mellitus (T2). 30342298 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE By combining the lowering serum triglyceride levels benefit of PPARα agonists (such as fibrates) with the glycemic advantages of the PPARγ agonists (such as TZD), the dual PPAR agonists approach can both improve the metabolic effects and minimize the side effects caused by either agent alone, and hence, has become a promising strategy for designing effective drugs against type-2 diabetes. 28853334 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Fenofibrate, a lipid-regulating peroxisome proliferator-activated receptor-α (PPARα) agonist, has been shown to reduce vascular complications in adults with type 2 diabetes. 29763709 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE This is the first PPARα/γ dual agonist reported to show this inhibitory effect representing the potential lead of a new class of drugs for treatment of dyslipidemic type 2 diabetes. 30199253 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE Assessment of the Pro12Ala Polymorphism in the PPAR-γ2 Gene among Type 2 Diabetes Patients in a Nigerian Population. 29621178 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Results showed that VK1 supplementation [1, 3, 5 μg/kg body weight (BW), 8 weeks] dose dependently improved the glucose tolerance; decreased BW gain, fasting glucose and insulin, glycated hemoglobin, HOMA-IR and cytokine secretion (monocyte chemoattractant protein-1 and interleukin-6); and regulated the signaling pathway of hepatic glucose metabolism [sirtuin 1 (SIRT1)/AMP-activated protein kinase (AMPK)/phosphoinositide 3-kinase/phosphatase and tensin homolog/glucose transporter 2/glucokinase/glucose 6 phosphatase], lipid oxidation (peroxisome proliferator-activated receptor alpha/carnitine palmitoyltransferase 1A) and inflammation (nuclear factor kappa B) in T2D mice. 29175667 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE We investigated the role of <i>microRNA-21</i> (<i>miR-21</i>) in regulating PPARα in DR. <i>miR-21</i> was overexpressed, while PPARα levels were decreased in the retina of <i>db/db</i> mice, a model of type 2 diabetes. 28270521 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Peroxisome proliferators-activated receptors (PPARα, γ and δ) are potentially effective targets for Type 2 diabetes mellitus therapy. 28186999 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE The aqueous extract of SC seeds exhibits significant insulin-sensitizing, antidyslipidemic, antioxidant, anti-inflammatory and β-cell salvaging activity in HFD-STZ-induced type 2 diabetic rats via overexpression of PPARγ and PPARα activity, affirming its potential to be used in the prevention and treatment of type 2 diabetes mellitus (T2DM). 28249245 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Histological results confirmed that renal expression of key proteins was reduced in DKD patients with respect to mitochondrial biogenesis (PGC-1α, p-AMPK) and FA oxidation (PPAR-α, CPT-1) as compared to that in the control and T2DM groups. 28956034 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE The Pro12Ala (rs1801282) polymorphism in peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) has been convincingly associated with insulin resistance (IR) and type 2 diabetes (T2D) among Europeans, in interaction with a high-fat diet. 27075119 2016
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Renal levels of PPARα were downregulated in both type 1 and type 2 diabetes models. 27543085 2016
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE We conducted a case control study to confirm the association of variants rs10885409 of TCF7L2 and Pro12Ala (rs1801282) of PPAR-γ2 with risk of T2DM and related complications in Emirati population of Arab origin. 26273662 2015
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE We used a two-stage study design to evaluate whether variations in the peroxisome proliferator-activated receptors (PPAR) and the PPAR gamma co-activator 1 (PGC1) gene families (PPARA, PPARG, PPARD, PPARGC1A, and PPARGC1B) are associated with type 2 diabetes (T2D) risk. 24359475 2014
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE We suggest that the PPARA L162V polymorphism may have diverse effects on serum lipids and CHD risk depends on the presence of T2DM. 23583468 2013
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE There is evidence that genetic variants within the PPARα gene have been associated with a risk of the development of dyslipidemia and cardiovascular disease by influencing fasting and postprandial lipid concentrations; the gene variants have also been associated with an acceleration of the progression of type 2 diabetes. 23858092 2013
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135-3.469) in a dominant model adjusted for age, gender and BMI. 23147557 2013
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE We investigated whether PPAR-γ2 gene polymorphisms are associated with serum lipids and the occurrence of coronary heart disease (CHD) prospectively characterised for the presence or absence of Type 2 diabetes in a Turkish population. 21833536 2011
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE These results indicate that PPARα is responsible for glucose production through the up-regulation of hepatic G6Pase gene expression during fasting or T2DM animal models. 21081500 2011